Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial Evaluating the Safety and Efficacy of Rituximab as Primary Treatment for Extensive Chronic Graft Versus Host Disease

NCT01161628 is registered in ClinicalTrials.gov with Northside Hospital, Inc. as lead sponsor.

NCT NCT01161628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01161628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial Evaluating the Safety and Efficacy of Rituximab as Primary Treatment for Extensive Chronic Graft Versus Host Disease
Lead sponsor
Northside Hospital, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2011
Completion date
July 31, 2015
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic graft-versus-host disease